title: Long-term GnRH agonist treatment for female central precocious puberty does not impair reproductive function.
abstract: Depot gonadotropin releasing hormone (GnRH) agonist (GnRHa) therapy is the treatment of choice for patients with central precocious puberty (CPP). It is still unclear whether long-term exposure to GnRHa is associated with impaired reproductive function in adulthood. The present study was performed on 46 women, former CPP patients, 12.5+/-3.7 years after the discontinuation of treatment with depot GnRHa. In a structured interview, we assessed general health status, clinical signs possibly associated with hyperandrogenism, menstrual cycle, gynaecological diseases and reproductive function. It appears that long-term treatment with depot GnRHa is safe and does not impair reproductive function. The risk of former CPP patients to develop hirsutism and/or polycystic ovary syndrome does not seem to be increased compared to the normal population but this issue needs to be addressed in further long-term follow-up studies.
authors.affiliation: Division of Paediatric Endocrinology, Department of Paediatrics, University Hospital, Kiel, Germany. sabine.heger@medizin.uni-leipzig.de
authors.forename: Sabine
authors.initials: S
authors.lastname: Heger
authors.forename: Marina
authors.initials: M
authors.lastname: Müller
authors.forename: Michael
authors.initials: M
authors.lastname: Ranke
authors.forename: Hans-Peter
authors.initials: HP
authors.lastname: Schwarz
authors.forename: Franz
authors.initials: F
authors.lastname: Waldhauser
authors.forename: Carl-Joachim
authors.initials: CJ
authors.lastname: Partsch
authors.forename: Wolfgang G
authors.initials: WG
authors.lastname: Sippell
mesh_terms: D000328:Adult; D000728:Androgens / Q000009:adverse effects; D001827:Body Height / Q000187:drug effects; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects; D003692:Delayed-Action Preparations / Q000008:administration & dosage; D004333:Drug Administration Routes; D005260:Female; D005298:Fertility / Q000187:drug effects; D005500:Follow-Up Studies; D005831:Genital Diseases, Female / Q000209:etiology; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000819:agonists* / Q000627:therapeutic use*; D006304:Health Status; D006801:Humans; D017588:Hyperandrogenism / Q000175:diagnosis; D007407:Interviews as Topic; D008134:Long-Term Care; D008597:Menstrual Cycle / Q000187:drug effects; D011629:Puberty, Precocious / Q000150:complications / Q000188:drug therapy*; D012098:Reproduction / Q000187:drug effects*; D017329:Triptorelin Pamoate / Q000627:therapeutic use
chemical_list: D000728:Androgens; D003692:Delayed-Action Preparations; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone